Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
IPO Year: 2018
Exchange: NASDAQ
Website: ymabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | $23.00 | Outperform | Oppenheimer |
| 8/16/2024 | $20.00 | Overweight | Cantor Fitzgerald |
| 6/28/2024 | $21.00 | Buy | Truist |
| 5/10/2023 | $5.00 → $13.00 | Neutral → Outperform | Wedbush |
| 4/3/2023 | Buy → Neutral | Guggenheim | |
| 1/27/2023 | $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/5/2023 | Outperform → Market Perform | Cowen | |
| 12/2/2022 | $23.00 → $5.00 | Buy → Neutral | BofA Securities |
| 12/2/2022 | Buy → Neutral | BofA Securities | |
| 10/31/2022 | $6.00 | Outperform → Neutral | Wedbush |
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial Officer role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, aft
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Mary Tagliaferri, M.D. to the Company's Board of Directors, effective February 29, 2024. Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors. "We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs," said
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
10-Q - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
10-Q - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, and Nobelpharma Co., Ltd. today announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma. Under the terms of the agreement, Nobelpharma will employ its
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):Investors (international):(877) 407-0792(201) 689-8263 To access a live webcast of the update,
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that its management team will participate in the following upcoming investor conferences: Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology SummitDate: Tuesday, October 8, 2024Time: 9:30 a.m. ETLocation: New York, NYPanel: "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes" BMO Oncology SummitDate: Tuesday, October 8, 2024Time: 3:00 p.m. ETL
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research ("AACR") Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada. Naxitamab maintains diseas
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: Friday, September 6, 2024Time: 1:50 p.m. ETLocation: New York, NYFormat: Fireside chat and investor 1x1 meetings Cantor Global Healthcare ConferenceDate: Tuesday, September 17, 2024Time: 3:40 p
Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increaseContinued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong KongPart A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran Norman LaFrance, M.D. as Chief Development Officer Cash and cash equivalents of $77.8 million held as of June 30, 2024, reflects $0.8 million cash burn in the six months ended June 30, 2024;
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare ConferenceDate: Tuesday, August 13, 2024Location: New York, NYFormat: Investor 1x1 meetings Canaccord Genuity 44th Annual Growth ConferenceDate: Wednesday, August 14, 2024Time: 8:00 a.m. ETLocation: Boston, MAFormat: Fireside chat and investor 1x1 meetings A live
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):(877) 407-0792Investors (international):(201) 689-8263 To access a live webcast of the update, please use this
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre
Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:
Jones Trading analyst Justin Walsh initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and announces Price Target of $23.
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects MSC Industrial Direct Co., Inc. (NYSE:MSM) to report quarterly earnings at $1.50 per share on revenue of $1.01 million before the opening bell, according to data from Benzinga Pro. MSC Industrial Direct shares gained 1.1% to $79.10 in the after-hours trading session. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) named Peter Pfreundschuh as Chief Financial Officer, effective June 28. Y-mAbs Therapeutics shares fell 2.3% to $11.56 in the after-hours trading session. Analysts are expecting Radius Recycling, Inc. (NASDAQ:RDUS) to post a quar
Pfreundschuh previously served as Chief Financial Officer at Voyager Therapeutics, Inc.
Truist Securities analyst Nicole Germino initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and announces Price Target of $21.
HC Wainwright & Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price target from $21 to $22.
2024 Financial GuidanceManagement reiterates its full year 2024 guidance:Anticipated total DANYELZA® net product revenues of between $95 million and $100 million;Anticipated operating expenses of between $115 million and $120 million;Anticipated total annual cash burn of between $15 million and $20 million; andCash and cash equivalents anticipated to continue to support operations as currently planned into 2027.
Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $19.931 million which missed the analyst consensus estimate of $22.220 million by 10.30 percent. This is a 1.58 percent decrease over sales of $20.251 million the same period last year.
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial Officer role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, after which it is expected that Mr. Kruse will be
Ratings for Y-mAbs Therapeutics (NASDAQ:YMAB) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.75, a high estimate of $26.00, and a low estimate of $21.00. Marking an increase of
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):Investors (international):(877) 407-0792(201) 689-8263 To access a live webcast of the update,
Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increaseContinued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong KongPart A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran Norman LaFrance, M.D. as Chief Development Officer Cash and cash equivalents of $77.8 million held as of June 30, 2024, reflects $0.8 million cash burn in the six months ended June 30, 2024;
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):(877) 407-0792Investors (international):(201) 689-8263 To access a live webcast of the update, please use this
Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumesCash and cash equivalents of $75.7 million as of March 31, 2024, and cash burn of only $2.9 million for the quarter ended March 31, 2024 Management reiterates full year 2024 financial guidance and anticipated cash runway into 2027The Company will host a conference call on Wednesday, May 8, 2024, at 8:00 a.m. ET NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NA
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Wednesday, May 8, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Bo Kruse, Chief Financial Officer; and Thomas Gad, Founder, Vice Chair and Chief Business Officer. C
Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December 31, 2023; Reiterate anticipated cash runway into 2027Management announces full year 2024 financial guidance The Company will host a conference call on Friday, March 1, 2024, at 8:00 a.m. ET NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, t
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 1, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Thomas Gad, Founder, Vice Chair and Chief Bu
Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59%U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin LymphomaCash and cash equivalents of $86.6 million as of September 30, 2023, with anticipated cash runway extended into 2027Management updates FY 2023 financial guidance by lowering anticipated operating expenses and use of cash The Company will host a conference call on Tuesday, November 14, 2023, at 9:00 a.m. ET NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 14, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Steen Lisby, Chief Scienti
Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00
Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00
Truist initiated coverage of Y-mAbs Therapeutics with a rating of Buy and set a new price target of $21.00
Wedbush upgraded Y-mAbs Therapeutics from Neutral to Outperform and set a new price target of $13.00 from $5.00 previously
Guggenheim downgraded Y-mAbs Therapeutics from Buy to Neutral
Morgan Stanley downgraded Y-mAbs Therapeutics from Equal-Weight to Underweight and set a new price target of $4.00
Cowen downgraded Y-mAbs Therapeutics from Outperform to Market Perform
BofA Securities downgraded Y-mAbs Therapeutics from Buy to Neutral and set a new price target of $5.00 from $23.00 previously
BofA Securities downgraded Y-mAbs Therapeutics from Buy to Neutral
Wedbush downgraded Y-mAbs Therapeutics from Outperform to Neutral and set a new price target of $6.00